Although scale-up of antiretroviral therapy (ART) since 2005 has contributed to declines of about 30% in the global annual number of human immunodeficiency (HIV)-related deaths and declines in global HIV incidence,[\*](#fn1-1097-1103){ref-type="fn"} estimated annual HIV-related deaths among adolescents have increased by about 50% ([@b1-1097-1103]) and estimated adolescent HIV incidence has been relatively stable.[†](#fn2-1097-1103){ref-type="fn"} In 2012, an estimated 2,500 (40%) of all 6,300 daily new HIV infections occurred among persons aged 15--24 years.[§](#fn3-1097-1103){ref-type="fn"} Difficulty enrolling adolescents and young adults in ART and high rates of loss to follow-up (LTFU) after ART initiation might be contributing to mortality and HIV incidence in this age group, but data are limited ([@b2-1097-1103]). To evaluate age-related ART retention challenges, data from retrospective cohort studies conducted in seven African countries among 16,421 patients, aged ≥15 years at enrollment, who initiated ART during 2004--2012 were analyzed. ART enrollment and outcome data were compared among three groups defined by age at enrollment: adolescents and young adults (aged 15--24 years), middle-aged adults (aged 25--49 years), and older adults (aged ≥50 years). Enrollees aged 15--24 years were predominantly female (81%--92%), commonly pregnant (3%--32% of females), unmarried (54%--73%), and, in four countries with employment data, unemployed (53%--86%). In comparison, older adults were more likely to be male (p\<0.001), employed (p\<0.001), and married, (p\<0.05 in five countries). Compared with older adults, adolescents and young adults had higher LTFU rates in all seven countries, reaching statistical significance in three countries in crude and multivariable analyses. Evidence-based interventions to reduce LTFU for adolescent and young adult ART enrollees could help reduce mortality and HIV incidence in this age group.

In each of seven countries (Côte d'Ivoire, Nigeria, Swaziland, Mozambique, Zambia, Uganda, and Tanzania), a representative sample of ART facilities was selected using either probability-proportional-to-size sampling or purposeful (nonrandom) sampling ([Table 1](#t1-1097-1103){ref-type="table"}). At each selected facility, a sample frame of study-eligible ART patients was created, and simple random sampling used to select the desired sample size. Eligibility criteria included having started ART during 2004--2012 and ≥6 months before data abstraction. Data were abstracted from ART medical records onto standard forms.

Mortality and LTFU were the primary outcomes of interest. A patient was considered LTFU if he/she had not attended the facility in the 90 days preceding data abstraction for a medication refill, a laboratory visit, or a clinician visit. Mortality ascertainment occurred largely through passive reporting to the health facility by family or friends, and to a lesser extent, through country-specific tracing activities to locate patients late for clinic appointments.

Study design was controlled for during analysis. Age at ART initiation was divided into three age categories ([@b3-1097-1103]): 15--24 years, 25--49 years, and ≥50 years. Differences in demographic and clinical characteristics across age groups were assessed using chi-square tests for categorical variables and unadjusted linear regression models for continuous variables.

To estimate the association between age group and rates of death and LTFU, Cox proportional hazards regression models were used to estimate unadjusted and adjusted hazard ratios for each outcome separately. For the multivariable analysis, to best manage missing baseline demographic or clinical data, multiple imputation with chained equations was used to impute missing data included in the model ([@b4-1097-1103]). Twenty imputed datasets were created for each outcome: death and LTFU ([@b4-1097-1103]). The imputation model included the event indicator, all study variables, and the Nelson-Aalen estimate of cumulative hazard ([@b4-1097-1103]). The proportional hazards assumption was assessed using visual methods and the Grambsch and Therneu test.

Demographic and clinical characteristics of adults at ART initiation were compared across age groups by country ([Table 2](#t2-1097-1103){ref-type="table"}). Age distribution was relatively constant across countries, with 5%--16% aged 15--24 years, 70%--86% aged 25--49 years, and 8%--14% aged ≥50 years. In all seven countries, the youngest age group was almost exclusively female (81%--92%), and the middle-age group mostly female (60%--68%); in contrast, the oldest age group was mostly male in all countries, except Nigeria. In the six countries with data on pregnancy at ART enrollment, pregnancy prevalence was highest in the youngest age group in five countries, where it ranged from 16% to 32%. In all seven countries, being married or in a civil union was least common in the youngest age group (27%--46%), reaching statistical significance in five countries. In the four countries with data on employment status, the youngest age group was least likely to be employed at the time of ART enrollment (14%--47%) (p\<0.05).

What is already known on this topic?

Although scale-up of antiretroviral therapy (ART) since 2005 has contributed to a decline of about 30% in the global annual number of human immunodeficiency (HIV)--related deaths and declines in global HIV incidence, estimated annual HIV-related deaths among adolescents have increased by about 50%, and estimated adolescent HIV incidence has been relatively stable. In 2012, an estimated 2,500 (40%) of all 6,300 daily new HIV infections occurred among persons aged 15--24 years. Difficulty enrolling adolescents and young adults in ART and high rates of loss to follow-up (LTFU) after ART initiation might be contributing to mortality and HIV incidence in this age group, but data are limited.

What is added by this report?

Age-related differences in enrollment characteristics and outcomes were analyzed among 16,421 patients aged ≥15 years starting ART in seven African countries (Côte d'Ivoire, Nigeria, Swaziland, Mozambique, Zambia, Uganda, and Tanzania) during 2004--2012. Patient characteristics and outcomes were compared across three age groups: adolescents and young adults (15--24 years), middle-aged adults (25--49 years), and older adults (≥50 years). Compared with older adults, adolescents and young adults had higher LTFU rates in all seven countries, reaching statistical significance in three countries (Côte d'Ivoire, Mozambique, and Tanzania) in both crude and multivariable analyses.

What are the implications for public health practice?

The higher risk for LTFU among adolescent and young adult ART enrollees, compared with older adults, increases their risk for death and increases the risk they will transmit HIV to seronegative sex partners. Effective interventions to reduce LTFU for adolescent and young adult ART enrollees could help reduce mortality and lower HIV incidence in this age group.

In all seven countries, median baseline weight was lowest in the youngest age group (48.2--58.0 kg), reaching statistical significance in six countries. In three countries (Nigeria, Swaziland, and Tanzania), prevalence of World Health Organization clinical stage 4 at ART initiation differed across age groups, tending to be lowest in the youngest and highest in the oldest age group (p\<0.05). Median baseline CD4 count was similar across age groups in all countries, except Nigeria, where the median was highest in the youngest age group (p=0.004). Median baseline hemoglobin was significantly lower in the youngest age group in four countries (9.4--10.7 g/dL).

Compared with older adults, rates of LTFU were higher in the youngest age group in all seven countries, reaching statistical significance in unadjusted analyses in three countries (Côte d'Ivoire (p=0.005), Mozambique (p\<0.001), and Tanzania (p=0.005)) ([Table 3](#t3-1097-1103){ref-type="table"}). Even after adjusting for baseline demographic and clinical characteristics, rates of LTFU were 1.66--2.45 times as high in the youngest compared with the oldest age group in these three countries (Côte d'Ivoire \[p=0.001\], Mozambique \[p=0.002\], and Tanzania \[p\<0.001\]).

In two countries (Swaziland and Uganda), the oldest age group had significantly higher rates of documented mortality than younger age groups ([Table 3](#t3-1097-1103){ref-type="table"}), and older age remained a significant predictor of mortality even in multivariable analyses.

Discussion
==========

The three main findings based on the experience of the seven African countries are as follows: 1) adolescents and young adults differed significantly from older adults in ART enrollment characteristics; 2) adolescents and young adults tended to have higher LTFU rates; and 3) in two countries (Uganda and Swaziland), adults ≥50 years had higher documented mortality rates.

Adolescent and young adult ART enrollees were almost exclusively female, commonly pregnant, unmarried, and unemployed. The observation that median weight was lowest among adolescents and young adults could be explained by expected weight-for-age growth, sex differences in weight, or undernutrition. Similarly, the observation that median hemoglobin tended to be lowest in the youngest age group might reflect predominantly female sex or higher prevalence of undernutrition.

Available data suggest that this group of predominantly female adolescent and young adult ART enrollees represents a socially vulnerable population ([@b2-1097-1103]). Although rates of HIV-related mortality and HIV incidence have declined globally since 2005, mortality has increased and HIV incidence remained relatively stable among adolescents, with the majority of adolescent deaths and new HIV infections occurring in sub-Saharan Africa ([@b2-1097-1103]). In African countries with generalized epidemics, being young, female, and unemployed increases the risk for voluntary or coerced sexual contact with older, HIV-infected men ([@b2-1097-1103]); this might partly explain HIV infection at a young age among some of the female adolescent and young adult ART enrollees described in this report. Factors that possibly explain high LTFU rates among adolescent and young adult ART enrollees might include stigma ([@b2-1097-1103]), lack of money for transport ([@b5-1097-1103]), child care responsibilities, and migration for work ([@b6-1097-1103]). LTFU from ART is associated with significant increases in mortality risk ([@b7-1097-1103]). A recent meta-analysis suggests that 20%--60% of patients lost to follow-up die, with most of these deaths occurring after default from ART ([@b7-1097-1103]). Therefore, difficulties in preventing LTFU among adolescent and young adults on ART might be a contributor to HIV-related mortality in this age group. Suboptimal ART adherence among adolescents might also be contributing to adolescent mortality ([@b1-1097-1103]).

High rates of LTFU among adolescent and young adult ART enrollees is also concerning from a prevention perspective, because LTFU patients are at risk for transmitting HIV to seronegative partners once ART is discontinued and viral load no longer suppressed ([@b8-1097-1103]). High rates of LTFU among young women, among whom the prevalence of pregnancy is high, also increases the likelihood of mother-to-child HIV transmission.

Adult ART enrollees aged ≥50 years were mostly male, commonly married, and employed. In two countries, this age group had higher documented mortality, similar to findings in other studies ([@b9-1097-1103]). Higher mortality in this oldest age group should probably be expected because of higher background rates of mortality in the older general population. However, HIV-related reasons for higher mortality in the oldest age group might include slower ART-induced CD4 restoration among older patients ([@b3-1097-1103]) or incidence of HIV-associated noncommunicable diseases, especially atherosclerotic disease ([@b10-1097-1103]).

The findings in this report are subject to at least four limitations. First, missing data might have introduced nondifferential measurement error. Second, because of differences in cohort size, there was greater power to detect covariate effect sizes in Côte d'Ivoire, Nigeria, Swaziland, and Mozambique than in Zambia, Uganda, and Tanzania. Third, in Zambia, Uganda, and Tanzania, clinics were purposefully selected, limiting generalizability of findings. Finally, limited active tracing for defaulting patients might have resulted in overestimates of LTFU and underestimates of mortality.

The main finding of this report is that adolescent and young adult ART enrollees differ significantly from older adults in demographic and clinical characteristics and are at higher risk for LTFU. Effective interventions to reduce LTFU for adolescent and young adult ART enrollees could help reduce mortality and HIV incidence in this age group.

Information available at <http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf>.

Sources: Kasedde S, Luo C, McClure C, Chandan U. Reducing HIV and AIDS in adolescents: opportunities and challenges. Curr HIV/AIDS Rep 2013;10:159--68; and UNAIDS. Report on the Global AIDS Epidemic, 2012, unpublished estimates; Spectrum 2012.

Information available at <http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/JC2434_WorldAIDSday_results_en.pdf>.

###### 

Summary of sampling strategies to select cohorts of enrollees for antiretroviral therapy (ART) --- seven African countries, 2004--2013

  Region and country    Stage 1: Selection of study facilities   Stage 2: Selection of study patients                                                                                                                                                                                                                                                                        
  --------------------- ---------------------------------------- -------------------------------------- ----------------------------------- ----------------------------------------------- -------------------------------------------------- ------------ --------- --------------------- ------------ ----- ------------ ------------------------------------------------ ----------------------
  **West Africa**                                                                                                                                                                                                                                                                                                                                                            
   Côte d'Ivoire        124 by Dec 2007                          36,943                                 Enrolled ≥50 adults by Dec 2007     78                                              36,110                                             PPS          34        Adults aged ≥15 yrs   2004--2007   SRS   4,000        3,682                                            Nov 2009--March 2010
   Nigeria              178 by Dec 2009                          168,335                                Enrolled ≥50 adults by Dec 2009     139                                             167,438                                            PPS          35        Adults aged ≥15 yrs   2004--2012   SRS   3,500        3,496                                            Dec 2012--Aug 2013
  **Southern Africa**                                                                                                                                                                                                                                                                                                                                                        
   Swaziland            31 by Dec 2009                           50,767                                 All ART initiation sites eligible   31                                              50,767                                             PPS          16        Adults aged ≥15 yrs   2004--2010   SRS   2,500        2,510                                            Nov 2011-- Feb 2012
   Mozambique           152 by Dec 2006                          43,295                                 Enrolled ≥50 adults by Dec 2006     94                                              42,234                                             PPS          30        Adults aged ≥15 yrs   2004--2007   SRS   2,600        2,596                                            Sept--Nov 2008
   Zambia               322 by Dec 2007                          65,383                                 Enrolled ≥300 adults by Dec 2007    129[\*](#tfn2-1097-1103){ref-type="table-fn"}   58,845[\*](#tfn2-1097-1103){ref-type="table-fn"}   Purposeful   6         Adults aged ≥15 yrs   2004--2009   SRS   1,500        1,214[†](#tfn3-1097-1103){ref-type="table-fn"}   April--July 2010
  **East Africa**                                                                                                                                                                                                                                                                                                                                                            
   Uganda               286 by Dec 2007                          45,946                                 Enrolled ≥300 adults by Dec 2007    114[\*](#tfn2-1097-1103){ref-type="table-fn"}   41,351[\*](#tfn2-1097-1103){ref-type="table-fn"}   Purposeful   6         Adults aged ≥15 yrs   2004--2009   SRS   1,500        1,466[§](#tfn4-1097-1103){ref-type="table-fn"}   April--July 2010
   Tanzania             210 by Dec 2007                          41,920                                 Enrolled ≥300 adults by Dec 2007    85                                              37,728[\*](#tfn2-1097-1103){ref-type="table-fn"}   Purposeful   6         Adults aged ≥18 yrs   2004--2009   SRS   1,500        1,457[¶](#tfn5-1097-1103){ref-type="table-fn"}   April--July 2010
  **Total**                                                      **452,589**                                                                **670**                                         **434,473**                                                     **133**                                            **17,100**   **16,421**                                       

**Abbreviations:** PPS = probability-proportional-to-size; SRS = simple random sampling.

Estimates based on available published data.

In Zambia, from 1,457 records sampled, 243 were excluded because of noncompliance with simple random sampling procedures at one site.

In Uganda, from 1,472 records samples, six patients were excluded because of absence of age data at ART initiation.

In Tanzania, from 1,458 records samples, one patient was excluded because of absence of age data at ART initiation.

###### 

Demographic and clinical characteristics of patients at initiation of antiretroviral therapy (ART) --- seven African countries, 2004--2012[\*](#tfn7-1097-1103){ref-type="table-fn"}

  Characteristic and age group (yrs)                           Côte d'Ivoire[†](#tfn9-1097-1103){ref-type="table-fn"} (N = 3,682)   Nigeria[†](#tfn9-1097-1103){ref-type="table-fn"} (N = 3,496)   Swaziland[†](#tfn9-1097-1103){ref-type="table-fn"} (N = 2,510)   Mozambique[†](#tfn9-1097-1103){ref-type="table-fn"} (N = 2,596)   Zambia (N = 1,214)   Tanzania (N = 1,457 )   Uganda (N = 1,466)                                                
  ------------------------------------------------------------ -------------------------------------------------------------------- -------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------- -------------------- ----------------------- -------------------- ------ ------- ------ ------- ------ ------- ------
  **Age at ART initiation (No. and %)**                                                                                                                                                                                                                                                                                                                                                                                                              
   15--24                                                      188                                                                  5%                                                             399                                                              11%                                                               398                  16%                     284                  12%    95      8%     83      6%     95      6%
   25--49                                                      3,087                                                                83%                                                            2,805                                                            81%                                                               1,759                70%                     2,069                79%    1,000   82%    1,198   82%    1,261   86%
   ≥50                                                         407                                                                  12%                                                            292                                                              9%                                                                353                  14%                     243                  10%    119     10%    176     12%    110     8%
  **Female (No. and %)**                                                                                                                                                                                                                                                                                                                                                                                                                             
   15--24                                                      166                                                                  87%                                                            366                                                              92%                                                               326                  82%                     45                   86%    82      86%    73      88%    77      81%
   25--49                                                      2,077                                                                68%                                                            1,808                                                            64%                                                               1,120                64%                     838                  60%    599     60%    813     68%    837     66%
   ≥50                                                         179                                                                  46%                                                            146                                                              51%                                                               175                  49%                     137                  48%    45      38%    87      49%    50      45%
   p--value                                                    **\<0.001**[§](#tfn9-1097-1103){ref-type="table-fn"}                 **\<0.001**                                                    **\<0.001**                                                      **\<0.001**                                                       **\<0.001**          **\<0.001**             **\<0.001**                                                       
  **Among females, pregnant (No. and %)**                                                                                                                                                                                                                                                                                                                                                                                                            
   15--24                                                      4                                                                    3%                                                             56                                                               16%                                                               82                   26%                     61                   30%    15      32%    ---     25     18%     
   25--49                                                      64                                                                   4%                                                             188                                                              10%                                                               117                  11%                     138                  14%    56      12%    ---     102    9%      
   ≥50                                                         0                                                                    0%                                                             0                                                                0%                                                                2                    1%                      0                    0%     0       0%     ---     0      0%      
   p-value                                                     0.567                                                                **\<0.001**                                                    **\<0.001**                                                      **0.002**                                                         **0.003**                                    **\<0.001**                                                       
  **Married/Civil union (No. and %)**                                                                                                                                                                                                                                                                                                                                                                                                                
   15--24                                                      41                                                                   27%                                                            177                                                              43%                                                               85                   28%                     99                   41%    38      46%    28      41%    21      34%
   25--49                                                      1,393                                                                50%                                                            1,795                                                            64%                                                               725                  47%                     999                  55%    520     60%    505     53%    431     43%
   ≥50                                                         202                                                                  54%                                                            200                                                              67%                                                               190                  65%                     113                  55%    67      64%    71      49%    40      43%
   Missing                                                     414                                                                  11%                                                            86                                                               2%                                                                384                  15%                     233                  9%     166     14%    299     21%    313     21%
   p-value                                                     **\<0.001**                                                          **\<0.001**                                                    **\<0.001**                                                      **0.001**                                                         **0.022**            0.115                   0.354                                                             
  **Employed (No. and %)**                                                                                                                                                                                                                                                                                                                                                                                                                           
   15--24                                                      59                                                                   47%                                                            91                                                               30%                                                               68                   31%                     28                   14%    ---     ---    ---                    
   25--49                                                      1,394                                                                63%                                                            1,541                                                            66%                                                               551                  48%                     860                  49%    ---     ---    ---                    
   ≥50                                                         148                                                                  53%                                                            165                                                              70%                                                               73                   32%                     104                  56%    ---     ---    ---                    
   Missing                                                     1,081                                                                29%                                                            420                                                              12%                                                               925                  37%                     328                  13%                                          
   p-value                                                     **\<0.001**                                                          **\<0.001**                                                    **\<0.001**                                                      **\<0.001**                                                                                                                                                                      
  **Baseline weight (No. and median \[kg\])**                                                                                                                                                                                                                                                                                                                                                                                                        
   15--24                                                      162                                                                  49.0                                                           371                                                              52.0                                                              356                  58.0                    223                  50.0   83      49.0   80      48.2   86      52.7
   25--49                                                      2,743                                                                53.0                                                           2589                                                             57.0                                                              1575                 60.0                    1,658                54.5   882     53.0   1,163   51.1   1,145   55.0
   ≥50                                                         351                                                                  54.0                                                           274                                                              57.0                                                              301                  59.9                    180                  52.5   108     55.0   172     50.2   101     56.0
   Missing                                                     426                                                                  12%                                                            262                                                              7%                                                                278                  11%                     535                  21%    141     12%    42      3%     134     9%
   p-value                                                     **0.005**                                                            **\<0.001**                                                    **0.024**                                                        **0.015**                                                         **0.001**            0.296                   **0.001**                                                         
  **WHO clinical stage 4 (No. and %)**                                                                                                                                                                                                                                                                                                                                                                                                               
   15--24                                                      25                                                                   18%                                                            25                                                               5%                                                                22                   6%                      32                   20%    11      13%    20      29%    12      14%
   25--49                                                      462                                                                  22%                                                            197                                                              8%                                                                218                  13%                     205                  15%    96      11%    257     27%    137     12%
   ≥50                                                         67                                                                   25%                                                            24                                                               11%                                                               53                   16%                     22                   15%    5       5%     48      35%    11      12%
   Missing                                                     1,101                                                                30%                                                            232                                                              7%                                                                290                  12%                     979                  38%    157     13%    293     20%    164     11%
   p-value                                                     0.468                                                                **0.012**                                                      **\<0.001**                                                      0.066                                                             0.100                **\<0.001**             0.551                                                             
  **Baseline CD4 count (No. and median \[cells/***μ***L\])**                                                                                                                                                                                                                                                                                                                                                                                         
   15--24                                                      165                                                                  122                                                            320                                                              192                                                               359                  158                     249                  175    69      147    50      175    76      161
   25--49                                                      2,811                                                                136                                                            2321                                                             157                                                               1618                 141                     1,794                157    701     128    933     126    1,011   133
   ≥50                                                         367                                                                  132                                                            244                                                              142                                                               319                  160                     211                  133    79      158    137     160    79      147
   Missing                                                     339                                                                  9%                                                             611                                                              17%                                                               214                  9%                      342                  13%    365     30%    337     23%    300     20%
   p-value                                                     0.216                                                                **0.004**                                                      0.139                                                            0.077                                                             0.704                0.243                   0.501                                                             
  **Baseline hemoglobin (No. and median \[g/dL\])**                                                                                                                                                                                                                                                                                                                                                                                                  
   15--24                                                      156                                                                  10.0                                                           190                                                              10.3                                                              229                  10.7                    211                  9.4    52      10.1   37      9.6    55      11.5
   25--49                                                      2,646                                                                9.9                                                            1,365                                                            10.3                                                              1165                 11.2                    1,515                10.2   582     10.6   648     10.2   748     11.9
   ≥50                                                         347                                                                  9.9                                                            145                                                              10.8                                                              218                  11.6                    173                  10.6   70      11.6   90      10.9   62      12.1
   Missing                                                     533                                                                  14%                                                            1,796                                                            51%                                                               898                  36%                     697                  27%    510     42%    682     47%    601     41%
   p-value                                                     0.524                                                                0.690                                                          **\<0.001**                                                      **\<0.001**                                                       **0.002**            **0.028**               0.306                                                             

**Abbreviation:** WHO = World Health Organization.

Although the study captured patient follow-up time through 2013, all patients started ART during the period 2004--2012.

Proportions from Côte d'Ivoire, Nigeria, Swaziland, and Mozambique are weighted to account for sampling design.

Bold-typed p-values are statistically significant (p\<0.05).

###### 

Association between age group at initiation of antiretroviral therapy and rates of loss to follow-up and death --- seven African countries, 2004--2013

  Country                                                   Age group (yrs)   No.     Lost to follow-up   Died                                                                                                                                                                               
  --------------------------------------------------------- ----------------- ------- ------------------- ------ -------------- ------------- ------ -------------- ----------------------------------------------------- ------ ------ -------------- ----------- ---------- -------------- -----------
  **Côte d'Ivoire**                                                                                                                                                                                                                                                                          
                                                            ≥50               407     14.5                1.00   ---            ---           1.00   ---            ---                                                   4.2    1.00   ---            ---         1.00       ---            ---
                                                            25--49            3,087   17.5                1.21   (0.92--1.59)   0.171         1.33   (1.00--1.77)   **0.052**[†](#tfn12-1097-1103){ref-type="table-fn"}   2.9    0.68   (0.45--1.05)   **0.077**   0.76       (0.51--1.12)   0.155
                                                            15--24            188     23.0                1.54   (1.15--2.04)   **0.005**     1.66   (1.24--2.22)   **0.001**                                             3.8    0.87   (0.37--2.03)   0.732       0.97       (0.43--2.18)   0.935
  **Nigeria**                                                                                                                                                                                                                                                                                
                                                            ≥50               399     15.3                1.00   ---            ---           1.00   ---            ---                                                   1.5    1.00   ---            ---         1.00       ---            ---
                                                            25--49            2,805   13.7                0.91   (0.70--1.18)   0.446         0.94   (0.73--1.22)   0.640                                                 1.1    0.79   (0.43--1.46)   0.441       0.89       (0.47--1.68)   0.714
                                                            15--24            292     16.5                1.09   (0.79--1.50)   0.604         1.04   (0.75--1.44)   0.818                                                 0.8    0.51   (0.20--1.34)   0.166       0.74       (0.30--1.86)   0.514
  **Swaziland**[§](#tfn13-1097-1103){ref-type="table-fn"}                                                                                                                                                                                                                                    
                                                            ≥50               353     11.0                1.00   ---            ---           1.00   ---            ---                                                   3.0    1.00   ---            ---         1.00       ---            ---
                                                            25--49            1,759   11.4                1.06   (0.91--1.23)   0.452         0.99   (0.81--1.20)   0.887                                                 1.9    0.66   (0.46--0.93)   **0.021**   **0.56**   (0.39--0.81)   **0.006**
                                                            15--24            398     13.2                1.26   (0.94--1.70)   0.113         1.22   (0.89--1.68)   0.198                                                 1.9    0.65   (0.46--0.92)   **0.018**   **0.58**   (0.38--0.90)   **0.019**
  **Mozambique**                                                                                                                                                                                                                                                                             
                                                            ≥50               243     16.4                1.00   ---            ---           1.00   ---            ---                                                   3.8    1.00   ---            ---         1.00       ---            ---
                                                            25--49            2,069   14.4                0.96   (0.78--1.18)   0.686         1.02   (0.79--1.32)   0.872                                                 3.2    0.94   (0.55--1.59)   0.805       1.10       (0.62--1.96)   0.733
                                                            15--24            284     28.4                1.80   (1.46--2.21)   **\<0.001**   1.76   (1.27--2.43)   **0.002**                                             5.0    1.40   (0.72--2.71)   0.296       1.33       (0.72--2.45)   0.339
  **Zambia**                                                                                                                                                                                                                                                                                 
                                                            ≥50               95      21.4                1.00   ---            ---           1.00   ---            ---                                                   3.6    1.00   ---            ---         1.00       ---            ---
                                                            25--49            1,000   21.7                1.01   (0.75--1.37)   0.928         0.94   (0.69--1.29)   0.722                                                 2.3    0.63   (0.29--1.33)   0.223       0.66       (0.30--1.47)   0.312
                                                            15--24            119     25.6                1.14   (0.75--1.74)   0.539         1.21   (0.78--1.89)   0.393                                                 5.1    1.32   (0.49--3.51)   0.582       1.26       (0.43--3.71)   0.679
  **Tanzania**                                                                                                                                                                                                                                                                               
                                                            ≥50               83      13.0                1.00   ---            ---           1.00   ---            ---                                                   8.0    1.00   ---            ---         1.00       ---            ---
                                                            25--49            1,198   17.8                1.36   (0.98--1.90)   **0.067**     1.47   (1.05--2.06)   **0.024**                                             6.4    0.80   (0.52--1.23)   0.309       0.90       (0.58--1.42)   0.661
                                                            15--24            176     30.1                2.01   (1.24--3.25)   **0.005**     2.45   (1.50--4.01)   **\<0.001**                                           13.5   1.37   (0.70--2.70)   0.358       1.40       (0.69--2.82)   0.354
  **Uganda**                                                                                                                                                                                                                                                                                 
                                                            ≥50               95      6.0                 1.00   ---            ---           1.00   ---            ---                                                   2.8    1.00   ---            ---         1.00       ---            ---
                                                            25--49            1,261   7.6                 1.29   (0.76--2.17)   0.346         1.37   (0.81--2.34)   0.240                                                 1.0    0.35   (0.15--0.80)   **0.013**   **0.31**   (0.13--0.76)   **0.010**
                                                            15--24            110     7.1                 1.18   (0.57--2.44)   0.664         1.19   (0.56--2.51)   0.647                                                 1.0    0.34   (0.07--1.66)   0.184       **0.25**   (0.05--1.29)   **0.098**

**Abbreviations:** HR = hazard ratio; CI = confidence interval; AHR = adjusted hazard ratio.

All variables presented in the table were included in the multivariable model for each country.

Bold-typed p-values are statistically significant (p\<0.05) or borderline significant (p=0.05--0.10).

In Swaziland, the study was designed to assess the effect of interfacility transfer of stable patients (down-referral) on risk for loss to follow-up, and this time-varying covariate was included in the multivariable model in addition to variables presented in the table.
